Managing Ductal Carcinoma In Situ (DCIS): Expert Insights on Breast Surgery Challenges

Defining and Diagnosing DCIS

• 💡 DCIS is defined as non-invasive breast cancer, where malignant cells are confined within the basement membrane of milk ducts, serving as a potential precursor to invasive disease.
• ⚠️ It's a challenging diagnosis to discuss with patients as it's staged as stage zero breast cancer, yet not all DCIS will progress to invasive cancer; it's considered a non-obligate precursor.
• 📈 The incidence of DCIS has significantly increased due to screening mammography, with about 90% of cases detected in asymptomatic women.

Clinical Challenges and Risk Stratification

• 🎯 A primary challenge is determining the risk of upgrade to invasive cancer, with studies showing up to 20-25% of DCIS cases on core biopsy have associated invasive cancer at surgical excision.
• 🔑 Another key challenge is assessing the future risk of progression of DCIS, with about half of recurrences being invasive.
• 🔬 Pathologic features like grade, hormone receptor status, and the presence of necrosis are crucial for understanding treatment options and future risk.

Surgical Management and Margins

• 🏥 Surgery is the first-line treatment for DCIS, with options including lumpectomy or mastectomy, chosen based on disease extent, patient factors (like hereditary mutations), and contraindications to radiation.
• 🎯 Achieving clear margins is critical for lumpectomy; a 2-millimeter margin is considered optimal to reduce recurrence risk, though this can be nuanced if radiation is planned.
• ❓ Sentinel lymph node biopsy is not routinely used for DCIS but may be considered if mastectomy is performed, anticipating a potential upgrade to invasive cancer.

Adjuvant Therapies and Risk Reduction

• 🌟 Adjuvant radiation after lumpectomy can reduce the risk of recurrence by half, though it does not impact overall survival.
• 📊 Tools like the MSKCC nomogram and tests like the Oncotype DX DCIS score or Prelude DX Decision RT test can help predict recurrence risk and potential benefit from radiation or endocrine therapy.
• 💊 Endocrine therapy (like tamoxifen or aromatase inhibitors) is an option for hormone receptor-positive DCIS, offering about a 30% risk reduction for recurrence and new contralateral breast cancers, with a lower dose/shorter duration option showing promise.

Evolving Management and the COMET Trial

• 🚀 The COMET trial suggests that active monitoring may be a viable option for select patients with low-risk, hormone receptor-positive DCIS, showing similar two-year rates of invasive cancer compared to surgery.
• ⚠️ However, the COMET trial has limitations, including short follow-up, a highly selected patient population, and significant crossover between treatment arms, highlighting the need for longer-term data.
• 💬 Shared decision-making is crucial, balancing patient preferences, the risks of overtreatment, and the benefits of various treatment modalities, including the option of lumpectomy alone which is a low-risk procedure.